2021 SITC Poster

by s2desi5_ksqtherapeutics | Nov 13, 2021 | Uncategorized

SITC Poster Presentation: “Development of KSQ-001, an Engineered TIL (eTIL®) Therapy for Solid Tumors through CRISPR/Cas9-mediated Inactivation of SOCS1”

by s2desi5_ksqtherapeutics | Nov 13, 2021 | Uncategorized

Click to download PDF file.

KSQ Therapeutics to Participate in Upcoming Investor Conferences

by bstone | Aug 28, 2024 | Uncategorized

Lexington, Mass., August 28, 2024 – KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing cancer therapies using its proprietary CRISPRomics® discovery platform, today announced that management will participate in the following investor...

SITC Poster Presentation: “KSQ-004: Unbiased Pair-wise Discovery of SOCS1 and Regnase-1 as the Top CRISPR/Cas9 Dual-edit Combination Enhancing In vivo TIL Potency Against Solid Tumors”

by s2desi5_ksqtherapeutics | Nov 13, 2021 | Uncategorized

Click image to enlarge. Click to download PDF file.

KSQ Therapeutics to Present Data at the American Association for Cancer Research (AACR) 2022 Annual Meeting

by s2desi5_ksqtherapeutics | Mar 22, 2022 | Uncategorized

– Data supports ongoing Phase 1 study of KSQ-4279, a first-in-class USP1 inhibitor, in patients with advanced solid tumors CAMBRIDGE, Mass., March 22, 2022- KSQ Therapeutics (KSQ), a clinical stage biotechnology company developing therapies to treat cancer and...